Table I.

Demographics and baseline clinical characteristics.

Category	Tanespimycin dose, mg/m²
Category	150 n = 4	220 n = 9	275 n = 3	340 n = 7	420 n = 3	525 n = 3	All dose cohorts N = 29
Age (years), median	58	63	54	71	58	63	63
Range	50–64	46–79	43–66	58–80	48–58	47–75	43–80
Sex
Male, n (%)	4 (100)	6 (67)	2 (67)	5 (71)	3 (100)	2 (67)	22 (76)
Ethnicity, n (%)
White	3 (75)	8 (89)	3 (100)	7 (100)	3 (100)	2 (67)	26 (90)
Black	1 (25)	0	0	0	0	1 (33)	2 (7)
Hispanic	0	1 (11)	0	0	0	0	1 (3)
KPS, median	90	90	90	90	90	90	90
Range	80–90	80–100	90–90	70–90	80–90	85–100	70–100
Subtype, n (%)
IgG	3 (75)	8 (89)	2 (67)	4 (57)	3 (100)	2 (67)	22 (76)
IgA	1 (25)	1 (11)	1 (33)	3 (43)	0	0	6 (21)
Nonsecretory	0	2 (22)	1 (33)	1 (14)	0	0	4 (14)
β₂ microglobulin, median (mg/l)	5·8	6·2	2·4	3·8	2·4	3·2	3·7
Median months since diagnosis	39	41	26	48	20	86	41
Any prior stem cell transplant, n (%)	3 (75)	3 (33)	0	3 (43)	1 (33)	2 (67)	12 (41)
Median number of prior regimens	4	5	4	4	3	6	4
Range	3–6	2–19	4–5	3–8	3–4	3–7	2–19
Prior bortezomib, n (%)	4 (100)	8 (89)	2 (67)	5 (71)	2 (67)	2 (67)	23 (79)
Prior lenalidomide, n (%)	2 (50)	3 (33)	1 (33)	2 (29)	0	0	8 (28)
Prior thalidomide, n (%)	2 (50)	8 (89)	3 (100)	6 (86)	3 (100)	3 (100)	25 (86)

KPS, Karnofsky performance status.